You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In a reader survey, researchers and core lab staff share how they think cores are doing.
The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.
A retrospective cohort study uncovered microRNA signatures that could tell lung cancer patients apart from others, including patients with other, non-tumor lung conditions.
The federal court order dismissed the case with prejudice, which prevents the plaintiffs from raising the case again.
The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
Direct-to-consumer genetic testing companies searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.